Overview

Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

Status:
NOT_YET_RECRUITING

Trial end date:
2026-11-14

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction

Phase:

PHASE2

Details

Lead Sponsor:

Beijing Inno Medicine Co., Ltd.

Treatments:

Glucose